BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1703 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1703\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07701239-11077@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SHR-1703: Phase 1 readout est. (NCT07701239)
DESCRIPTION:SHR-1703\, phase 1.\nStudy: A Study Comparing a Pre-filled Safe
 ty Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participa
 nts\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/shr-1703#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07701239
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653322-11077@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SHR-1703: Phase 3 readout est. (NCT06653322)
DESCRIPTION:SHR-1703\, phase 3.\nStudy: A Multi-centered，Randomized，Dou
 ble-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety o
 f SHR-1703 in Eosinophilic Asthma\nEstimated primary completion: September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1703#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06653322
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441812-11077@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SHR-1703: Phase 2 readout est. (NCT06441812)
DESCRIPTION:SHR-1703\, phase 2.\nStudy: A Study to Evaluate the Long-term S
 afety\, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma P
 atients\nEstimated primary completion: September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/shr-1703#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06441812
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05979051-11077@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SHR-1703: Phase 2/3 readout est. (NCT05979051)
DESCRIPTION:SHR-1703\, phase 2/3\, Eosinophilic Granulomatosis with Polyang
 iitis.\nStudy: A Study to Evaluate the Efficacy and Safety of SHR-1703 in 
 Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/shr-1703#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05979051
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
